Immunopharmacology

Transgenic and knockout models in renin-angiotensin system
pp. 1-7(7)
Authors: Murakami K.; Fukamizu A.

Role of the bradykinin B₂ receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice
pp. 9-13(5)
Authors: Madeddu P.; Emanueli C.; Gaspa L.; Salis B.; Milia A.F.; Chao L.; Chao J.

Structure of a kallikrein-like enzyme and its tissue localization in the dog
pp. 15-19(5)
Authors: Sasaguri M.; Noda K.; Tsuji E.; Koga M.; Kinoshita A.; Ideishi M.; Ogata S.; Arakawa K.

Angioedema due to angiotensin-converting enzyme inhibitors
pp. 21-25(5)
Authors: Agostoni A.; Cicardi M.; Cugno M.; Zingale L.C.; Gioffre D.; Nussberger J.

ACE-inhibition attenuates cardiac cell damage and preserves release of NO in the postischemic heart
pp. 27-33(7)
Authors: Zahler S.; Kupatt C.; Becker B.F.

Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes
pp. 35-42(8)
Authors: Tschope C.; Walther T.; Yu M.; Reinecke A.; Koch M.; Seligmann C.; Heringer S.B.; Pesquero J.B.; Bader M.; Schultheiss H.-P.; Unger T.

Therapeutic advantage of angiotensin converting enzyme inhibitors in chronic glomerulonephritis
pp. 43-48(6)
Authors: Omata K.; Saito T.; Sato H.; Sato T.; Abe F.; Yamada M.; Yaoita H.; Endo Y.; Ito S.; Kanazawa M.; Abe K.

A secretory mechanism of renal kallikrein by a high potassium ion; a possible involvement of ATP-sensitive potassium channel
pp. 49-55(7)
Authors: Hayashi I.; Fujita T.; Majima M.; Katori M.

Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats
pp. 57-65(9)
Authors: Dobrzynski E.; Yoshida H.; Chao J.; Chao L.

Endothelin-1 and endothelin receptor status in kidney transplants undergoing acute rejection
pp. 67-74(8)
Authors: Naicker S.; Gathiram P.; Naidoo S.; Nadar A.; Muller-Esterl W.; Bhoola K.D.

Plasma kallikrein localisation in human blood vessels
pp. 75-80(6)
Authors: Cerf M.; Raidoo D.; Fink E.; Fritz H.; Bhoola K.

Expression of kininogen genes by rat cardiomyocytes
pp. 81-85(5)
Authors: Nagaoka M.; Yayama K.; Takano M.; Okamoto H.

Regulatory role of bradykinin in the coronary and cerebral circulations and in systemic hemodynamics
pp. 87-92(6)
Authors: Volpe A.R.; Fontecchio G.; Carmignani M.

The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats
pp. 93-98(6)
Authors: Abbas S.A.; Sharma J.N.; Yusof A.P.M.

Mechanisms of bradykinin-induced catecholamine release in pithed spontaneously hypertensive rats
pp. 99-104(6)
Authors: Dendorfer A.; Fitschen M.; Raasch W.; Tempel K.; Dominiak P.

Kininergic system and arterial hypertension following chronic exposure to inorganic lead
pp. 105-110(6)
Authors: Carmignani M.; Boscolo P.; Poma A.; Volpe A.R.

Upregulation of the cardiac bradykinin B2 receptors after myocardial infarction
pp. 111-117(7)
Authors: Tschope C.; Koch M.; Spillmann F.; Heringer-Walther S.; Mochmann H.-C.; Stauss H.; Bader M.; Unger T.; Schultheiss H.-P.; Walther T.

Increased coagulation and bradykinin-release in shed pleural blood during cardiac surgery
pp. 119-122(4)
Authors: Wendel H.P.; Eckstein F.S.; Fink E.; Jurmann M.J.; Scheule A.M.; Haberle L.; Ziemer G.

LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein
pp. 123-127(5)
Authors: Fujita H.; Yoshikawa M.

Bradykinin-potentiating peptides and C-type natriuretic peptides from snake venom
pp. 129-135(7)
Authors: Higuchi S.; Murayama N.; Saguchi K.; Ohi H.; Fujita Y.; Camargo A.C.M.; Ogawa T.; Deshimaru M.; Ohno M.

Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery
pp. 137-143(7)
Authors: Murakami H.; Miao R.Q.; Chao L.; Chao J.

Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention
pp. 145-152(8)
Authors: Majima M.; Hayashi I.; Fujita T.; Ito H.; Nakajima S.; Katori M.

The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor
pp. 153-159(7)
Authors: Ura N.; Higashiura K.; Shimamoto K.

Culture of human renal tubular cells: positive selection of kallikrein-containing cells
pp. 161-167(7)
Authors: Carr T.; Evans P.; Campbell S.; Bass P.; Albano J.

K⁺ loading, but not Na⁺ loading, and blockade of ATP-sensitive K⁺ channels augment renal kallikrein secretion
pp. 169-175(7)
Authors: Fujita T.; Hayashi I.; Kumagai Y.; Inamura N.; Masataka Majima

Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8 years later
pp. 177-182(6)
Authors: Smith C.; Campbell S.; Albano J.; Clark A.; Gavin Millar

Tissue kallikrein and kinins in renal disease
pp. 183-192(10)
Authors: Naicker S.; Naidoo S.; Ramsaroop R.; Moodley D.; Bhoola K.

Changes in prostacyclin, thromboxane A₂ and F₂-isoprostanes, and influence of eicosapentaenoic acid and antiplatelet agents in patients with hypertension and hyperlipidemia
pp. 193-198(6)
Authors: Yamada M.; Omata K.; Abe F.; Ito S.; Keishi Abe

Specific direct radioimmunoassay of angiotensin II (AT II) in human plasma and the effect of angiotensin converting enzyme (ACE) inhibitor
pp. 199-204(6)
Authors: Abe F.; Omata K.; Yamada M.; Tsunoda K.; Sato T.; Shimizu T.; Ito S.; Abe K.; Nakazima M.; Morimoto T.; Takanashi N.

Postnatal development of cyclooxygenase-2 in the rat kidney
pp. 205-210(6)
Authors: Vio C.P.; Balestrini C.; Recabarren M.; Cespedes C.